Technical Analysis for DNL - Diurnal Group Plc

Grade Last Price % Change Price Change
C 71.5 0.70% 0.50
DNL closed up 0.7 percent on Friday, April 16, 2021, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical DNL trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Multiple of Ten Bullish Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 0.70%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.70%
Stochastic Reached Oversold Weakness 0.70%
Multiple of Ten Bullish Other 0.70%
Wide Bands Range Expansion 0.70%
Older End-of-Day Signals for DNL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low 2 days ago
Down 5% 2 days ago
Down 3% 2 days ago
Down 2% 2 days ago
Down 1% 2 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Diurnal Group Plc Description

Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company's products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism. The Company's products are under various clinical trials, including Chronocort, which is in Phase III clinical trial; Infacort, which is in Phase III clinical trial, and Native Oral Testosterone, which is in Phase I clinical trial.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Clinic Cement Therapy Clinical Trial Alcohols Organ Systems Hormones Idis Thyroid Endocrine System Hypogonadism Testosterone

Is DNL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 97.975
52 Week Low 27.0001
Average Volume 247,983
200-Day Moving Average 57.02
50-Day Moving Average 66.34
20-Day Moving Average 75.85
10-Day Moving Average 76.25
Average True Range 4.45
ADX 31.93
+DI 24.45
-DI 25.11
Chandelier Exit (Long, 3 ATRs ) 84.63
Chandelier Exit (Short, 3 ATRs ) 75.95
Upper Bollinger Band 89.45
Lower Bollinger Band 62.25
Percent B (%b) 0.34
BandWidth 35.86
MACD Line 2.23
MACD Signal Line 3.77
MACD Histogram -1.5473
Fundamentals Value
Market Cap 98.91 Million
Num Shares 138 Million
EPS -19.70
Price-to-Earnings (P/E) Ratio -3.63
Price-to-Sales 7.17
Price-to-Book 3.57
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 77.80
Resistance 3 (R3) 77.33 74.77 76.75
Resistance 2 (R2) 74.77 73.16 75.00 76.40
Resistance 1 (R1) 73.13 72.17 73.95 73.60 76.05
Pivot Point 70.57 70.57 70.98 70.80 70.57
Support 1 (S1) 68.93 68.96 69.75 69.40 66.95
Support 2 (S2) 66.37 67.97 66.60 66.60
Support 3 (S3) 64.73 66.37 66.25
Support 4 (S4) 65.20